key: cord-0859720-crj0yqmx
authors: Hu, Jin; Ma, Linlin; Wang, Huiqiang; Yan, Haiyan; Zhang, Dajun; Li, Zhuorong; Jiang, Jiandong; Li, Yuhuan
title: A novel benzo-heterocyclic amine derivative N30 inhibits influenza virus replication by depression of Inosine-5’-Monophospate Dehydrogenase activity
date: 2017-03-15
journal: Virol J
DOI: 10.1186/s12985-017-0724-6
sha: 5d89d3273a8590afe87b37195d47f7e0c00d777c
doc_id: 859720
cord_uid: crj0yqmx

BACKGROUD: Influenza virus is still a huge threat to the world-wide public health. Host inosine-5’- monophosphate dehydrogenase (IMPDH) involved in the synthesis of guanine nucleotides, is known to be a potential target to inhibit the replication of viruses. Herein, we evaluated antiviral activity of a benzo-heterocyclic amine derivative N30, which was designed to inhibit IMPDH. RESULTS: The results demonstrated that N30 inhibited the replication of H1N1, H3N2, influenza B viruses, including oseltamivir and amantadine resistant strains in vitro. Mechanistically, neuraminidase inhibition assay and hemagglutination inhibition assay suggested that N30 did not directly target the two envelope glycoproteins required for viral adsorption or release. Instead, the compound could depress the activity of IMPDH type II. Based on these findings, we further confirmed that N30 provided a strong inhibition on the replication of respiratory syncytial virus, coronavirus, enterovirus 71 and a diverse strains of coxsackie B virus. CONCLUSIONS: We identified the small molecule N30, as an inhibitor of IMPDH, might be a potential candidate to inhibit the replication of various viruses.

Influenza A virus (IAV) is extremely prone to cause periodic epidemics and pandemics in the world through evolution by point mutations or swapping of gene segments, correspondingly [1] [2] [3] .

At present, vaccination and antiviral drugs are principle strategies to prevent influenza. Available anti-influenza drugs include inhibitors of neuraminidase (NA) (e.g. oseltamivir and zanamivir) [4] , M2 proton channel (amantadine and rimantadine) [5] , and RNA-dependent RNA polymerase (RdRp) (favipiravir) [6] . However, influenza vaccines must be reformulated each year due to the constant antigenic evolution of influenza. Additionally, NA inhibitors and M2 ion-channel inhibitors have limited efficacies as drug resistance occurrence [7, 8] , and they only worked at the early phase of virus infection. The inherent property of influenza viruses to mutate, resulting in low efficacy of available drugs, has underscored the necessity of developing alternative strategies to provide protection against pandemic influenza.

Widespread utilization of directly antiviral drugs accelerates resistance problem, hence host cellular factors become attractive therapeutic targets to treat influenza virus infections. Recent studies were pioneered in host purine metabolic pathway, a conserved process responsible for providing host cells with a ready supply of guanosine triphosphate (GTP) for critical cellular processes [9] . Host cells could produce GTP either in de novo pathway or salvage pathway. While in the de novo synthesis of GTP, IMPDH catalyzes the oxidation of inosine monophosphate (IMP) to xanthosine monophosphate (XMP) which is the rate-limiting step. Growing evidences support that inhibition of IMPDH decreases intracellular levels of guanosine nucleotides in DNA or RNA synthesis, thereby indirectly inhibits virus replication which requires host guanine nucleotides as raw materials [10, 11] . As IMPDH inhibitors targeted on host cells, it would be less susceptible for selection of drugresistant strains.

In early study, we established a series of novel benzoheterocyclic amine derivatives and determined their in vitro antiviral activities. Notably, compounds 3d (N30) showed potent activity towards IAV at low micromolar concentrations [12] . In the present study, we developed the broad-spectrum antiviral activity of N30 in vitro, including oseltamivir-resistant strains and amantadineresistant strains of influenza virus, coxsackie B virus, coronavirus, and respiratory syncytial virus. In addition, we examined the inhibitory rate of the compound against two IAV envelope glycoproteins, hemagglutinin and neuraminidase, and investigated its effect on expression and the enzyme activity of IMPDH type II. Our results indicated that N30 is a potential compound with antiviral activities through suppressing the activity of IMPDH type II, these finding also proves that development of anti-influenza drugs directing at IMPDH is warranted.

Compounds N30 (N-(4-nitrophenyl methyl) benzothiazole-6-amine, Fig. 1a ) was originally provided by Professor Zhuorong Li at the Institute of Medicinal Bioechnology Chinese Academy of Medical Sciences, Beijing, China. Pirodavir (Biochempartner), oseltamivir carboxylate (OC, Medchem), amantadine hydrochloride (AH, Sigma-Aldrich) and Ribavirin (RBV, Sigma-Aldrich) were used as reference drugs in vitro. N30, pirodavir and AH were dissolved in dimethyl sulfoxide (DMSO, Sigm-Aldrich). OC and RBV were dissolved at phosphate buffered saline (PBS, Gbico).

Cells in this study were all purchased from the America Type Culture Collection (ATCC). Madin-Darby canine kidney (MDCK) cells were grown in Minimum Essential Medium (MEM, Invitrogen) containing 1% Non-Essential Amino Acids Solution (NEAA, Invitrogen), 1% Penicillin-Streptomycin (10,000 U/mL) (Invitrogen) and 10% fetal bovine serum (FBS, Gbico). African green monkey kidney (Vero) cells and Human lung embryonated cells (MRC-5) cells were cultured in MEM supplemented with 1% antibiotics and 10% or 15% FBS respectively. While Hep2 cells were grown in DMEM / F12 (1:1) (Invitrogen) supplemented with 1% antibiotics and 10% FBS. Cells were cultured at 37°C in the presence of 5% CO 2 . For influenza virus infections, MDCK cells were washed with PBS and infected with influenza virus diluted in serum-free medium at 37°C for 2 h. Then, the viral inoculum was replaced by maintenance medium supplemented with 2 μg/ml TPCK-treated trypsin (Worthington) and 0.08% BSA (Sigma-Aldrich). As for other virus infections, virus was diluted in serum-free medium and incubated with cells at 37°C for 1 h. Then, the viral inoculum was replaced by maintenance medium supplemented with 2% FBS.

The cytotoxicity of N30 in MDCK, Vero, Hep2, and MRC-5 was evaluated by Cell Counting Kit (CCK, Transgen Biotech). Briefly, cells were seeded in 96-well culture plates (MDCK cells were 2.5 × 10 4 per well, Hep2 cells were 1 × 10 4 per well, Vero and MRC-5 cells were 4 × 10 4 per well). 16 h later, cells were incubated with serial two-fold dilutions of N30 for another 48 h. Then, 10 μL of CCK was added to cells, the absorbance was read at 450 nm on Enspire (Perkin Elmer) after 4 hours incubation. The TC 50 (defined as the 50% toxicity concentration of drugs) were determined by Reed and Muench method [13] .

The attached cells were incubated with virus (100 TCID 50 ) in serum-free medium for 2 h at 37°C. The unconjugated viruses were replaced by maintenance medium with serial two-fold dilutions of N30 or positive control drugs. The reduction of virus-induced CPE were recorded when the CPE in viral control groups reached 100%, then according to Reed and Muench method, 50% cell-inhibitory concentrations (IC 50 ) and selectivity index (SI, calculated as the ratio of TC 50 /IC 50 ) of compounds were calculated [14] .

Cells were collected at 24 h post-infection and lysed in M-PER mammalian protein extraction reagent containing halt protease inhibitor cocktail (Thermo Fisher Scientific), sample proteins were subjected to SDS-PAGE and transferred to PVDF membrane (Millipore). After blocked with 5% milk, the membranes were incubated with antibodies against Influenza M2, β-actin (Santa Cruz), CVB3 VP1 (Millipore), IMPDH type II (Sigma-Aldrich), RSV M2 (Santa Cruz) and coronavirus (FIPV-70, Santa Cruz) respectively, then, the HRPconjugated secondary antibodies were incubated and the signals were detected using an enhanced chemiluminescence (ECL) kit (GE Healthcare Life Sciences).

Total RNA was extracted at 24 h post-infection and purified using the RNeasy Mini Kit (Qiagen). The onestep quantitative real-time RT-PCR was carried out using an ABI 7500 Fast real-time PCR instrument The experiments were performed in triplicate, and the data represents mean ± SD. ***P < 0.001 versus Con (ANOVA) (Applied Biosystems) using SuperScript III Platinum SYBR Green One-Step qRT-PCR kit (Transgen) with the following conditions: 50°C for 5 min, 95°C for 30 seconds, followed by 35 cycles of 95°C for 5 s, 60°C for 30 s. The mRNA of IAV M2, CVB3 VP1, RSV M2, and GAPDH were amplified with specific primers (Oligonucleotides used were shown in Table 1 ) [15, 16] . The samples were normalized by subtracting the CT values of GAPDH and the relative amounts of viral RNA were calculated.

The inhibition activity were assessed by quantifying the fluorescent product of the enzymatic reaction upon the cleavage of 4-methylumbelliferyl-a-D-N-acetylneuraminic acid (MUNANA). Briefly, the 100 μL reaction system consisted of 20 μL sample, 20 μL enzyme and 60 μL substrate buffer mix (20 μM MUNANA, 33 mM MES buffer (pH 3.5), 4 mM CaCl 2 , double distilled water). 60 μL substrate buffer mix was added after incubating diluted drug samples and enzyme for 60 min at room temperature. The fluorescence intensity was read before and after incubating for 15 min on Enspire Multimode Reader (PerkinElmer), with excitation and emission wavelength were 355 nm and 460 nm respectively. The relative fluorescence were obtained by subtracting the background value [15] .

The inhibitory effect of compound N30 on viral attachment to target cells was assessed by HI assay using a 1.2% chicken red blood cell suspension. Briefly, the diluted IAV were mixed with diluted compounds in a U bottom 96-well plate. After incubation at 4°C for 40 min, equal volume of 1.2% chicken erythrocyte suspension was added to each well. Then, the erythrocyte aggregation was evaluated by visual inspection after 40 min [17, 18] .

The enzymatic assay was employed to evaluate the inhibitory effect of N30 on the activity of IMPDH type II by following the increase in formation of nicotinamideadenine dinucleotide (NADH), which absorbance was read at 340 nm on Enspire at 30°C. The 200 μL assay buffer contained 1 M Tris/HCl (pH 8.8), 1 M KCl, 30 mM EDTA, 10 μL IMPDH type II (Sigma-Aldrich), 1 mM DTT and NAD (Sigma-Aldrich). The reaction was started after addition of IMP, with final concentrations was 1 mM [19] .

The cytotoxic effect of N30 on cell viabilities including MDCK, Vero, MRC-5 and Hep2 cells were measured with CCK, illustrated in Fig. 1b . According to the results of cytotoxicity, we selected non toxicity dose to implement subsequent experiments. Antiviral activity of N30 against influenza viruses were obtained by the method of CPE in MDCK cells, with RBV, OC and AH as reference drugs. IC 50 and SI values of N30 against influenza viruses were shown in Table 2 Furthermore, as displayed in Fig. 2b, N30 could not inhibit the aggregation of chicken erythrocytes caused by viral hemagglutinin binding to sialic acid receptors on the cellular membrane surface, while negative control drugs RBV or OC also did not show the inhibitory effect as they are not targeted on HA [1, 20] . The results suggested N30 probably does not target on two IAV envelope glycoproteins required for virus adsorption or release, the antiviral effect of N30 is more likely attribute to inhibiting one or multiple intracellular replication process of influenza virus.

Ribavirin had been demonstrated to possess a broad activity against several RNA and DNA viruses, including influenza A and B virus [21] , measles virus, Parainfluenza virus and so on [22] [23] [24] . IMPDH had been demonstrated to play a critical role in viral suppression of RBV-MP, the phosphorylated form of RBV. Accumulating evidence showed that depression of IMPDH inhibits replication of diverse species of viruses. N30 was synthesized targeting on IMPDH, so we further studied the effect of N30 on the enzyme. The results showed that IMPDH expressions have not been lessened after N30 treatment, even RBV had no inhibition either. On the other hand, the enzymatic reaction rate of IMPDH could be reduced by 38.18% after N30 treatment. Hence, the anti-influenza activity of N30 might be related to the inhibition the IMPDH-driven enzymatic reaction (Fig. 3) .

Extensive pharmacological activity of IMPDH inhibitors has been researched and some has been applied in clinic. Considering the products of IMPDH catalyzed reaction are necessary for viral replication, N30 should also exhibit inhibitory effects on other viruses. In support of this hypothesis, we tested the ability of N30 to protect cells from infection of virus, such as EV71, CVB, RSV and coronavirus.

As exhibited in Tables 3 and 4 , N30 showed antiviral activities against different strains of EV71 (reference drug pirodavir) or CVB (reference drug RBV). In addition, N30 suppressed CVB3 structural protein 1 (VP1) mRNA and protein expressions in a dose dependent manner (Fig. 4a) .

Next, we evaluated the inhibitory action of N30 on RSV and Coronavirus replication. As presented in Fig. 4b , N30 markedly decreased the RSV M2 mRNA and protein expressions in RSV-infected Hep2 cells, Moreover, 10 μM N30 treatment almost completely inhibit the expression of the viral proteins. Additionally, a similar suppression of N30 towards coronavirus was displayed in Fig. 4c .

Taken together, our data identified N30 possessed a broad spectrum antiviral activity against different strains of CVB and EV71, RSV and coronavirus in vitro.

To determine the in vivo toxicity of N30 preliminarily, female Kun Ming mice were gavaged 100 mg/kg and 50 mg/kg N30 twice a day. Six mice enrolled in each group were gavaged with N30 or vehicle for continuous administration for 14 days, then weighted at day 0, 5, 10 and 14 respectively, shown in Table 5 . The body weight changes of mice were observed in groups. We found there were no significant differences between the N30 group and vehicle-treated control group (5% CH 3 CH 2 OH + 5%

Castor oil was applied as the parallel solvent control.). This indicates that the dose of 100 mg/kg by oral administration in mice had little acute toxicity.

For a long time, infection with numerous different viruses has brought prodigious threat to human health. Influenza viruses display considerable antigenic diversity, and new strains arising from antigenic mutation always cause pandemics over the world. Therefore, a key challenge is searching for novel drug targets with broad antiviral spectrum and difficult to generate viral resistance. As we know, viruses always use a host protein or signaling pathway to complete its replication, therefore host factors are attractive therapeutic targets to treat virus infections. The experiments were performed in triplicate, and the data represents mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 versus Con IMPDH controls the conversion of IMP to XMP, which is the rate-limiting step in de novo synthesis of guanine nucleotides [25] . Since guanine, as the raw material in replication of virus, needs to be synthesized by host cells, inhibition of IMPDH could restrain virus replication eventually. Even if an organism or tissue can produce guanine nucleotides in salvage pathways through several phosphoribosyl transferases [26] , the amount of guanine nucleotides can not meet the need for rapidly growing cells or viruses. So, the replication of influenza virus could be inhibited through downregulating guanine nucleotides synthesis by inhibiting the activity of IMPDH. IMPDH activity is determined by two highly conserved isoforms type I and type II in human and mammalian cells [27] , which show different biological functions [28] . The comparation of N30 on the two subtypes of IMPDH is worth doing in the future.

In our study, we demonstrated the antiviral effect of N30 against influenza virus, including resistant strains against oseltamivir and amantadine. We have excluded the target of neuraminidase or hemagglutinin and found its antiviral mechanism may involve the inhibition of guanine nucleotides synthesis by inhibiting the activity of IMPDH type II. As IMPDH is necessary for viral replication, the antiviral effect of N30 on EV71, CVB, RSV and coronavirus has been confirmed. In addition, N30 showed little toxicity in vivo on survival rate or body weight in mice, and we will further detect the antiviral efficacy of N30 in vivo. Based on the above results, we believe that studying N30 or other IMPDH inhibitors has prospect future in antiviral research.

Although many IMPDH inhibitors have been developed, their biological function and mechanism are still needed to be studied. In addition, the current application of IMPDH inhibitors has some side effects. In early studies on influenza virus-infected patients, RBV administered orally elevated the bilirubin values. This may reflect the destruction of the RBV-containing erythrocytes. In Lassa fever infected patients, when treated orally or intravenously with higher doses of RBV, a transient anemia was also observed [29] . Besides, the side effects limited the use of mycophenolate mofetil (MMF, another IMPDH inhibitor) either, such as diarrhea, leucopenia, sepsis, and vomiting, and adverse effects on fetal researches occurred in experimental animals [30] . These highlight an urgent need to reduce the toxicity of IMPDH inhibitors. Therefore, we will perform more extensive laboratory studies on N30 in pharmacokinetics, pesticide effect, and toxicity in vivo to provide a theoretical basis for its druggability.

N30 inhibited the replication of H1N1, H3N2, influenza B viruses, including oseltamivir and amantadine resistant strains in vitro. N30 did not directly target the two envelope glycoproteins required for viral adsorption or release. Instead, the compound could depress the activity of IMPDH type II. N30 provided a strong inhibition on the replication of respiratory syncytial virus, coronavirus, enterovirus 71 and a diverse strains of coxsackie B virus. 

Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses

Influenza Virus M2 Protein Ion Channel Activity Helps To Maintain Pandemic 2009 H1N1 Virus Hemagglutinin Fusion Competence during Transport to the Cell Surface

The Nucleoprotein of Newly Emerged H7N9 Influenza A Virus Harbors a Unique Motif Conferring Resistance to Antiviral Human MxA

Influenza A Virus Neuraminidase Limits Viral Superinfection

Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block

T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro

Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models

Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation

Different Characteristics and Nucleotide Binding Properties of Inosine Monophosphate Dehydrogenase (IMPDH) Isoforms

De novo GTP Biosynthesis Is Critical for Virulence of the Fungal Pathogen Cryptococcus neoformans

Synthesis and broad-spectrum antiviral activity of some novel benzo-heterocyclic amine compounds

Antiviral activities of extracts from Hong Kong seaweeds

Identification of Traditional Medicinal Plant Extracts with Novel Anti-Influenza Activity

Antiviral Activities of Several Oral Traditional Chinese Medicines against Influenza Viruses

Characterization of human coronavirus etiology in Chinese adults with acute upper respiratory tract infection by real-time RT-PCR assays

Preparation and diagnostic utility of a hemagglutination inhibition test antigen derived from the baculovirus-expressed hemagglutinin-neuraminidase protein gene of Newcastle disease virus

Serological Response in RT-PCR Confirmed H1N1-2009 Influenza A by Hemagglutination Inhibition and Virus Neutralization Assays: An Observational Study

CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations

Hepatitis C eradication: A long way to go

Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro

Biochemistry and clinical applications of ribavirin

A heterocyclic molecule with significant activity against dengue virus

Inhibitory action of polyunsaturated fatty acids on IMP dehydrogenase

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models

Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system

Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients

News and challenges in the treatment of hepatitis C in liver transplantation

The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients

The datasets used during the current study available from the corresponding author on reasonable request.Authors' contributions JH participated in the design of the study and drafted the manuscript. LM coordinated the experimental design and helped edit the manuscript. HW and HY performed viral infection, qRT-PCR assay, and western blotting. DZ provided the compound N30. JJ, ZL and YL helped coordinated the experimental design. All authors read and approved the final manuscript.

The authors declare that they have no competing interests.

Ethics approval and consent to participate Not applicable.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

• We accept pre-submission inquiries • Our selector tool helps you to find the most relevant journal Submit your next manuscript to BioMed Central and we will help you at every step: